Karyopharm Therapeutics Will Update On Endometrial Cancer Program Following US FDA Meet
Karyopharm Therapeutics Will Update On Endometrial Cancer Program Following US FDA Meet
Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it is in discussions and has an upcoming meeting with the U.S. Food and Drug Administration (FDA) regarding the evolving treatment landscape in endometrial cancer and any implications this may have with respect to the Company's Phase 3 XPORT-EC-042 trial. In light of this, Karyopharm does not plan to discuss its endometrial cancer program during the Piper Sandler 36th Annual Healthcare Conference being held in New York, NY today. The Company intends to provide an update on its endometrial cancer program as soon as practical following the discussion with FDA.
Karyopharm Therapeutics Inc.（纳斯达克：KPTI）是一家商业阶段的药品公司，致力于开创新的癌症疗法，今天宣布它正在与美国食品和药品管理局（FDA）进行讨论，并将于即将召开的会议上讨论子宫内膜癌的治疗现状，以及这可能对公司的第三阶段XPORt-EC-042试验有什么影响。考虑到这一点，Karyopharm不打算在今天于纽约举行的派杰投资第36届年度医疗保健会议上讨论其子宫内膜癌项目。公司计划在与FDA讨论后尽快提供关于其子宫内膜癌项目的更新。
